Metformin and contrast-induced acte kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infraction: Amulticenter study
IF 4.638; International audience; AIM : To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI).METHODS: Patients with type 2 diabetes mellitus (T2DM) treated with PCI 27μmol/l (0.3mg/dl) or >50% over baseline after PCI. Since PCI was urgent, metformin could not be withheld prior to PCI but was usually stopped after PCI.RESULTS:Among the 372 patients included, 147 (40%) were using metformin, which had older diabetes, but had risk factors similar to patients without metformin. Baseline eGFR was better in pati…
016: Evidence of systemic plaque vulnerability in acute coronary syndromes with FDG-positron emission tomography and computed tomographic angiography in the BIOCORE-2 study
PurposeAtherosclerotic plaque vulnerability is a systemic phenomenon and is often associated with severe plaque infiltration with inflammatory cells. 18-Fluoro-deoxyglucose (FDG) accumulates in inflammatory cells of atherosclerotic plaques. The aim of this study was to assess whether 1) FDG uptake in the aorta and carotid arteries measured by positron emission tomography (PET) is higher in patients with acute coronary syndromes (ACS) than in patients with stable coronary artery disease (CAD) and; 2) associated with morphological markers of plaque instability detected with computed tomography angiography (CTA).MethodsPatients with ACS (n=50) or stable CAD (n=28) underwent a PET 90 minutes af…